Clinical Trial

Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

Study acronym: BIOSEP
Recruiting
View on ClinicalTrials.gov →
Summary
Objectives: 1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection. 2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis. 3. To determine the long term cognitive and physical sequelae of sepsis after admission.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-11.
Trial Details
NCT Number NCT06178822
Lead Sponsor Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Collaborators: Amsterdam UMC, location VUmc, Flevoziekenhuis
Conditions Sepsis, Septic Shock, Sepsis, Severe, Infections, Infection Viral, Infection, Bacterial, Infections, Respiratory
Enrollment 3,300 participants
Start Date 2022-10-25
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-02